Bilharzia or schistosomiasis is a parasitic disease due to infestation by a hematophagous trematode of the genus Schistosoma. It is the second most frequent parasitic endemic in the world after malaria. The most frequent tissue infections are intestinal and genitourinary. Testicular localizations of schistosoma are very rare. When lesions become chronic, they present as non-specific masses, bilharziomas, posing enormous problems of differential diagnosis with other benign and malignant pathologies, which impacts management. We report a case of epididymal schistosomiasis in a 37 years old patient simulating a malignant tumor. This case allowed us to review the diagnostic difficulties of this rare localization and the challenges of management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149191 | PMC |
http://dx.doi.org/10.1016/j.idcr.2023.e01770 | DOI Listing |
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Yantai Yuhuangding Hospital Affiliated to Qingdao University, Yantai, Shandong, China.
Background: Adverse events (AE) in dupilumab induced ocular surface diseases (DIOSD) have raised concerns regarding its safety. The objective of this study was to evaluate DIOSD by employing database analysis and clinical case review, along with mechanism analysis.
Research Design And Methods: Database AE data were extracted from FAERS from 2017 Quarter 1 (Q1) to 2023 Q1.
J Vitreoretin Dis
December 2024
Dartmouth Hitchcock Medical Center, Department of Surgery, Ophthalmology Section, Lebanon, NH, USA.
To describe the efficacy of belzutifan as a treatment for juxtapapillary retinal hemangioblastomas in patients with von Hippel-Lindau disease. A case and its findings were analyzed, and a systematic literature review was conducted using PubMed and Ovid MEDLINE. At a routine follow-up, a 63-year-old woman with a history of von Hippel-Lindau disease and slowly progressive bilateral juxtapapillary retinal hemangioblastomas presented with decreased visual acuity (VA) in the right eye resulting from significant lesion growth and an increase in central macular edema and exudate.
View Article and Find Full Text PDFFront Immunol
January 2025
Department of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Background: Radical cystectomy (RC) combined with pelvic lymph node dissection (PLND) is the standard treatment for muscle-invasive bladder cancer (MIBC). For metastatic MIBC patients, platinum-based chemotherapy remains the first choice treatment. However, approximately 50% of patients with metastatic MIBC are ineligible for platinum-based adjuvant chemotherapy because of impaired renal function.
View Article and Find Full Text PDFFront Med (Lausanne)
December 2024
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Background: Rhabdomyosarcoma (RMS), a rare pediatric soft tissue neoplasm, predominantly develops in late childhood and adolescence with no discernible gender bias. Alveolar rhabdomyosarcoma (ARMS) stems from mesenchymal cells and may develop most frequently in the trunk, extremities, and head/neck areas, while occurrences in the pelvic cavity are less frequent. The manifestation is typically characterized by a high rate of aggressive metastasis and a poor overall survival prognosis.
View Article and Find Full Text PDFDiscoveries (Craiova)
September 2024
Department of Oncopathology, Homi Bhabha Cancer Hospital (HBCH) and Mahamana Pandit Madan Mohan Malviya Cancer Centre (MPMMCC), Tata Memorial Centre, Homi Bhabha National Institute (HBNI), Varanasi, India.
Breast sarcomas are a diverse group of malignant neoplasms originating from the mammary stroma. They are uncommon tumors, often occurring as a component of other tumors. Among malignant breast mesenchymal tumors, pure sarcomas lacking epithelial components are even rarer, comprising only 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!